Literature DB >> 20717122

The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production.

Adel Helmy1, Keri L H Carpenter, David K Menon, John D Pickard, Peter J A Hutchinson.   

Abstract

The role of neuroinflammation is increasingly being recognised in a diverse range of cerebral pathologies, including traumatic brain injury (TBI). We used cerebral microdialysis and paired arterial and jugular bulb plasma sampling to characterise the production of 42 cytokines after severe TBI in 12 patients over 5 days. We compared two microdialysis perfusates in six patients: central nervous system perfusion fluid and 3.5% human albumin solution (HAS); 3.5% HAS has a superior fluid recovery (95.8 versus 83.3%), a superior relative recovery in 18 of 42 cytokines (versus 8 of 42), and a qualitatively superior recovery profile. All 42 cytokines were recovered from the human brain. Sixteen cytokines showed a stereotyped temporal peak, at least twice the median value for that cytokine over the monitoring period; day 1: tumour necrosis factor, interleukin (IL)7, IL8, macrophage inflammatory protein (MIP)1α, soluble CD40 ligand, GRO, IL1β, platelet derived growth factor (PDGF)-AA, MIP1β, RANTES; day 2: IL1 receptor antagonist (ra). IL6, granulocyte-colony stimulating factor (G-CSF), chemokine CXC motif ligand 10 (IP10); days 4 to 5: IL12p70, IL10. Brain extracellular fluid concentrations were significantly higher than plasma concentrations for 19 cytokines: basic fibroblast growth factor (FGF2), G-CSF, IL1α, IL1β, IL1ra, IL3, IL6, IL8, IL10, IL12p40, IL12p70, IP10, monocyte chemotactic protein (MCP)1, MCP3, MIP1α, MIP1β, PDGF-AA, transforming growth factor (TGF)α and vascular endothelial growth factor. No clear arterio-jugular venous gradients were apparent. These data provide evidence for the cerebral production of these cytokines and show a stereotyped temporal pattern after TBI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717122      PMCID: PMC3049520          DOI: 10.1038/jcbfm.2010.142

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

Review 1.  Role of cerebral inflammation after traumatic brain injury: a revisited concept.

Authors:  M C Morganti-Kossmann; M Rancan; V I Otto; P F Stahel; T Kossmann
Journal:  Shock       Date:  2001-09       Impact factor: 3.454

2.  Inflammation in the nervous system--physiological and pathophysiological aspects.

Authors:  Marianne Schultzberg; Catharina Lindberg; Asa Forslin Aronsson; Erik Hjorth; Stefan D Spulber; Mircea Oprica
Journal:  Physiol Behav       Date:  2007-05-24

Review 3.  Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury.

Authors:  Courtney L Robertson; Susanna Scafidi; Mary C McKenna; Gary Fiskum
Journal:  Exp Neurol       Date:  2009-05-07       Impact factor: 5.330

4.  Cerebral microdialysis of interleukin (IL)-1beta and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats.

Authors:  Hedy Folkersma; John J P Brevé; Fred J H Tilders; Leela Cherian; Claudia S Robertson; W Peter Vandertop
Journal:  Acta Neurochir (Wien)       Date:  2008-11-25       Impact factor: 2.216

Review 5.  Modulation of immune response by head injury.

Authors:  Maria Cristina Morganti-Kossmann; Laveniya Satgunaseelan; Nicole Bye; Thomas Kossmann
Journal:  Injury       Date:  2007-11-28       Impact factor: 2.586

Review 6.  Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells.

Authors:  Nils P Hailer
Journal:  Prog Neurobiol       Date:  2007-12-23       Impact factor: 11.685

7.  Long-term intracerebral inflammatory response after traumatic brain injury.

Authors:  S M Gentleman; P D Leclercq; L Moyes; D I Graham; C Smith; W S T Griffin; J A R Nicoll
Journal:  Forensic Sci Int       Date:  2004-12-16       Impact factor: 2.395

Review 8.  Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs.

Authors:  Adel Helmy; Keri L H Carpenter; Peter J Hutchinson
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.

Authors:  Simon R Clark; Catherine J McMahon; Iva Gueorguieva; Malcolm Rowland; Sylvia Scarth; Rachel Georgiou; Pippa J Tyrrell; Stephen J Hopkins; Nancy J Rothwell
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-08       Impact factor: 6.200

Review 10.  Consensus meeting on microdialysis in neurointensive care.

Authors:  Bo-Michael Bellander; Emmanuel Cantais; Per Enblad; Peter Hutchinson; Carl-Henrik Nordström; Claudia Robertson; Juan Sahuquillo; Martin Smith; Nino Stocchetti; Urban Ungerstedt; Andreas Unterberg; Niels Vidiendal Olsen
Journal:  Intensive Care Med       Date:  2004-11-10       Impact factor: 17.440

View more
  143 in total

Review 1.  Update on multimodality monitoring.

Authors:  Chad M Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Osteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injury.

Authors:  Julie L Chan; Thomas M Reeves; Linda L Phillips
Journal:  Exp Neurol       Date:  2014-08-21       Impact factor: 5.330

3.  Diffuse Intracranial Injury Patterns Are Associated with Impaired Cerebrovascular Reactivity in Adult Traumatic Brain Injury: A CENTER-TBI Validation Study.

Authors:  Frederick A Zeiler; François Mathieu; Miguel Monteiro; Ben Glocker; Ari Ercole; Erta Beqiri; Manuel Cabeleira; Nino Stocchetti; Peter Smielewski; Marek Czosnyka; Virginia Newcombe; David K Menon
Journal:  J Neurotrauma       Date:  2020-04-06       Impact factor: 5.269

4.  IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study.

Authors:  Matthew L Diamond; Anne C Ritter; Michelle D Failla; Jennifer A Boles; Yvette P Conley; Patrick M Kochanek; Amy K Wagner
Journal:  Epilepsia       Date:  2014-04-22       Impact factor: 5.864

5.  2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine inhibit TNF-α and CXCL10 production from activated primary murine microglia via A2A receptors.

Authors:  Elizabeth A Newell; Jennifer L Exo; Jonathan D Verrier; Travis C Jackson; Delbert G Gillespie; Keri Janesko-Feldman; Patrick M Kochanek; Edwin K Jackson
Journal:  Brain Res       Date:  2014-11-03       Impact factor: 3.252

Review 6.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

Review 7.  A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?

Authors:  Ruchira M Jha; Patrick M Kochanek
Journal:  Curr Neurol Neurosci Rep       Date:  2018-11-07       Impact factor: 5.081

8.  Cerebrospinal Fluid NLRP3 is Increased After Severe Traumatic Brain Injury in Infants and Children.

Authors:  Jessica S Wallisch; Dennis W Simon; Hülya Bayır; Michael J Bell; Patrick M Kochanek; Robert S B Clark
Journal:  Neurocrit Care       Date:  2017-08       Impact factor: 3.210

9.  Hemorrhagic shock shifts the serum cytokine profile from pro- to anti-inflammatory after experimental traumatic brain injury in mice.

Authors:  Steven L Shein; David K Shellington; Jennifer L Exo; Travis C Jackson; Stephen R Wisniewski; Edwin K Jackson; Vincent A Vagni; Hülya Bayır; Robert S B Clark; C Edward Dixon; Keri L Janesko-Feldman; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2014-08-15       Impact factor: 5.269

10.  In vivo microdialysis sampling of cytokines from rat hippocampus: comparison of cannula implantation procedures.

Authors:  Thaddeus W Vasicek; Matthew R Jackson; Tina M Poseno; Julie A Stenken
Journal:  ACS Chem Neurosci       Date:  2013-04-02       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.